How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances.
British Journal of Clinical Pharmacology January 14, 2020 DOI: 10.1111/bcp.14183 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Key points | The abstract proposes that deaths can aid clinicians and policy-makers in comprehending the risks associated with novel psychoactive substances. |
Abstract
How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances.
Citations in the library
Cited by 3
- New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Experimental Neurology May 1, 2021
- Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients Frontiers in Psychiatry August 31, 2020
- The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. Psychopharmacology June 1, 2022